Annual SGA
$100.23 M
-$38.37 M-27.68%
December 31, 2023
Summary
- As of February 8, 2025, AKBA annual SGA is $100.23 million, with the most recent change of -$38.37 million (-27.68%) on December 31, 2023.
- During the last 3 years, AKBA annual SGA has fallen by -$53.87 million (-34.96%).
- AKBA annual SGA is now -42.44% below its all-time high of $174.14 million, reached on December 31, 2021.
Performance
AKBA SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$26.52 M
-$401.00 K-1.49%
September 30, 2024
Summary
- As of February 8, 2025, AKBA quarterly SGA is $26.52 million, with the most recent change of -$401.00 thousand (-1.49%) on September 30, 2024.
- Over the past year, AKBA quarterly SGA has dropped by -$401.00 thousand (-1.49%).
- AKBA quarterly SGA is now -51.89% below its all-time high of $55.12 million, reached on December 31, 2018.
Performance
AKBA Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$6.53 B
-$45.99 M-0.71%
September 30, 2024
Summary
- As of February 8, 2025, AKBA TTM SGA is -$6.53 billion, with the most recent change of -$45.99 million (-0.71%) on September 30, 2024.
- Over the past year, AKBA TTM SGA has dropped by -$6.63 billion (-6594.42%).
- AKBA TTM SGA is now -5036.43% below its all-time high of -$127.07 million.
Performance
AKBA TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
AKBA Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.7% | -1.5% | -6594.4% |
| 3 y3 years | -35.0% | -40.8% | -3848.1% |
| 5 y5 years | +15.1% | -40.8% | -3848.1% |
AKBA Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -42.4% | at low | -40.8% | +16.8% | -20.2% | at low |
| 5 y | 5-year | -42.4% | at low | -42.8% | +16.8% | -139.5% | at low |
| alltime | all time | -42.4% | +3367.1% | -51.9% | +3870.7% | -5036.4% | at low |
Akebia Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $26.52 M(-1.5%) | $104.31 M(+3.8%) |
| Jun 2024 | - | $26.92 M(+5.8%) | $100.50 M(-0.1%) |
| Mar 2024 | - | $25.44 M(+0.0%) | $100.62 M(+0.4%) |
| Dec 2023 | $100.23 M(-27.7%) | $25.44 M(+12.0%) | $100.23 M(-4.3%) |
| Sep 2023 | - | $22.71 M(-16.0%) | $104.71 M(-8.1%) |
| Jun 2023 | - | $27.04 M(+7.9%) | $113.88 M(-4.4%) |
| Mar 2023 | - | $25.05 M(-16.2%) | $119.09 M(-13.9%) |
| Dec 2022 | $138.60 M(-20.4%) | $29.91 M(-6.2%) | $138.36 M(-9.7%) |
| Sep 2022 | - | $31.89 M(-1.1%) | $153.26 M(-8.6%) |
| Jun 2022 | - | $32.24 M(-27.3%) | $167.73 M(-5.3%) |
| Mar 2022 | - | $44.33 M(-1.1%) | $177.14 M(+1.7%) |
| Dec 2021 | $174.14 M(+13.0%) | $44.80 M(-3.4%) | $174.14 M(+2.6%) |
| Sep 2021 | - | $46.36 M(+11.3%) | $169.80 M(+3.8%) |
| Jun 2021 | - | $41.65 M(+0.8%) | $163.61 M(+3.9%) |
| Mar 2021 | - | $41.33 M(+2.1%) | $157.44 M(+2.2%) |
| Dec 2020 | $154.10 M(+3.1%) | $40.46 M(+0.7%) | $154.10 M(-2.8%) |
| Sep 2020 | - | $40.17 M(+13.2%) | $158.55 M(+3.9%) |
| Jun 2020 | - | $35.48 M(-6.6%) | $152.56 M(-0.4%) |
| Mar 2020 | - | $37.98 M(-15.4%) | $153.15 M(+2.5%) |
| Dec 2019 | $149.46 M(+71.7%) | $44.92 M(+31.4%) | $149.46 M(-6.4%) |
| Sep 2019 | - | $34.18 M(-5.2%) | $159.66 M(+17.5%) |
| Jun 2019 | - | $36.07 M(+5.2%) | $135.86 M(+20.9%) |
| Mar 2019 | - | $34.29 M(-37.8%) | $112.33 M(+29.0%) |
| Dec 2018 | $87.06 M | $55.12 M(+431.1%) | $87.06 M(+120.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $10.38 M(-17.2%) | $39.51 M(+10.1%) |
| Jun 2018 | - | $12.54 M(+38.9%) | $35.88 M(+18.6%) |
| Mar 2018 | - | $9.02 M(+19.3%) | $30.24 M(+12.0%) |
| Dec 2017 | $27.01 M(+21.6%) | $7.57 M(+12.1%) | $27.01 M(+5.6%) |
| Sep 2017 | - | $6.75 M(-2.3%) | $25.59 M(+7.6%) |
| Jun 2017 | - | $6.91 M(+19.3%) | $23.78 M(+7.2%) |
| Mar 2017 | - | $5.79 M(-5.8%) | $22.19 M(-0.1%) |
| Dec 2016 | $22.21 M(+20.1%) | $6.14 M(+24.3%) | $22.21 M(+1.5%) |
| Sep 2016 | - | $4.94 M(-6.9%) | $21.87 M(+4.1%) |
| Jun 2016 | - | $5.31 M(-8.6%) | $21.00 M(+4.6%) |
| Mar 2016 | - | $5.81 M(+0.1%) | $20.07 M(+8.5%) |
| Dec 2015 | $18.50 M(+26.0%) | $5.81 M(+42.5%) | $18.50 M(+0.7%) |
| Sep 2015 | - | $4.07 M(-7.1%) | $18.36 M(+6.6%) |
| Jun 2015 | - | $4.38 M(+3.6%) | $17.23 M(+13.7%) |
| Mar 2015 | - | $4.23 M(-25.4%) | $15.16 M(+3.3%) |
| Dec 2014 | $14.68 M(+108.7%) | $5.67 M(+93.3%) | $14.68 M(+5.6%) |
| Sep 2014 | - | $2.94 M(+26.8%) | $13.89 M(+18.2%) |
| Jun 2014 | - | $2.31 M(-38.3%) | $11.75 M(+16.3%) |
| Mar 2014 | - | $3.75 M(-23.3%) | $10.10 M(+43.7%) |
| Dec 2013 | $7.03 M(+143.2%) | $4.89 M(+515.9%) | $7.03 M(+228.4%) |
| Sep 2013 | - | $794.00 K(+18.9%) | $2.14 M(+59.0%) |
| Jun 2013 | - | $667.80 K(-1.6%) | $1.35 M(+98.4%) |
| Mar 2013 | - | $678.90 K | $678.90 K |
| Dec 2012 | $2.89 M | - | - |
FAQ
- What is Akebia Therapeutics annual SGA?
- What is the all time high annual SGA for Akebia Therapeutics?
- What is Akebia Therapeutics annual SGA year-on-year change?
- What is Akebia Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly SGA year-on-year change?
- What is Akebia Therapeutics TTM SGA?
- What is the all time high TTM SGA for Akebia Therapeutics?
- What is Akebia Therapeutics TTM SGA year-on-year change?
What is Akebia Therapeutics annual SGA?
The current annual SGA of AKBA is $100.23 M
What is the all time high annual SGA for Akebia Therapeutics?
Akebia Therapeutics all-time high annual SGA is $174.14 M
What is Akebia Therapeutics annual SGA year-on-year change?
Over the past year, AKBA annual SGA has changed by -$38.37 M (-27.68%)
What is Akebia Therapeutics quarterly SGA?
The current quarterly SGA of AKBA is $26.52 M
What is the all time high quarterly SGA for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly SGA is $55.12 M
What is Akebia Therapeutics quarterly SGA year-on-year change?
Over the past year, AKBA quarterly SGA has changed by -$401.00 K (-1.49%)
What is Akebia Therapeutics TTM SGA?
The current TTM SGA of AKBA is -$6.53 B
What is the all time high TTM SGA for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM SGA is -$127.07 M
What is Akebia Therapeutics TTM SGA year-on-year change?
Over the past year, AKBA TTM SGA has changed by -$6.63 B (-6594.42%)